Changchun Hi-Tech (000661.SZ) subsidiary's application for marketing licensing of Baike Bio's live attenuated nasal spray influenza vaccine was accepted
Changchun Hi-Tech (000661.SZ) issued an announcement. The company's subsidiary Changchun Baike Biotechnology Co., Ltd. (abbreviated as “...
Southwest Securities released a research report on April 22 stating that it gave Changchun Hi-Tech (000661.SZ) a purchase rating. The main reasons for the rating include: 1) steady growth in growth hormone; 2) continued dosage of the shingles vaccine; 3)
Southwest Securities released a research report on April 22 stating that it gave Changchun Hi-Tech (000661.SZ) a purchase rating. The main reasons for the rating include: 1) steady growth in growth hormone; 2) continued dosage of the shingles vaccine; 3) the proprietary Chinese medicine business has remained stable, and the real estate sector is growing rapidly. (Mainichi Keizai Shimbun)
Express News | Changchun Hi-Tech: Subsequent real estate sector will continue to focus on sales and make every effort to eliminate inventory
Changchun Hi-Tech (000661): Revenue is growing steadily, and new products are ready to go
Revenue grew steadily, and the new Jinsai/Baike product was ready to launch. The target price was 200.80 yuan. The “purchase” of Changchun Hi-Tech achieved 1Q24 revenue of 3.18 billion yuan (+14.4% yoy), and a net profit of 859 million yuan (+14.4% yoy).
Changchun Hi-Tech (000661): Increased proportion of long-term growth hormone continues to be realized in the research pipeline
Incident: The company released its 2024 quarterly report, achieving operating income of 3.18 billion yuan, an increase of 14.4% over the previous year; achieved net profit attributable to shareholders of the parent company of 860 million yuan, an increase of 0.2% over the previous year; achieved net profit after deduction
Express News | Changchun Hi-Tech: Net profit of 859 million yuan in the first quarter of 2024 increased 0.2% year-on-year
Changchun Hi-Tech (000661.SZ): Application for marketing of injectable triprorelin acetate microspheres accepted
Gelonghui, April 18 | Changchun Hi-Tech (000661.SZ) announced, Changchun Hi-Tech (000661.SZ) announced that the subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. received the “Notice of Acceptance” approved and issued by the State Drug Administration, and Jinsai Pharmaceutical's marketing application for injectable triprorelin acetate microspheres was accepted. The company's injectable triprorelin acetate microsphere products improve drug safety by improving drug release characteristics, optimizing prescriptions and processes, and making it possible for pediatric patients to administer fixed doses. A more convenient method of administration supported by evidence-based medical evidence will be central precocious puberty (C
Heavy warehouse bought back Meituan Kuaishou! Zhong Geng Qiu Dongrong's quarterly report revealed that there were many moves to adjust positions
Early this morning, Qiu Dongrong's products revealed a quarterly report.
Express News | Qiu Dongrong bought gold stocks in the first quarter
Changchun Hi-Tech (000661.SZ) plans to pay 45 yuan for 10 shares to be deducted from interest on April 18
Changchun Hi-Tech (000661.SZ) announced that the company's 2023 equity distribution plan: 45 yuan (tax included) for every 10 shares; the exclusion date is: April 18, 2024.
Express News | Changchun Hi-Tech: Subsidiary's application for marketing of injectable kinazumab accepted
Tianfeng Securities released a research report on April 11 stating that it gave Changchun Hi-Tech (000661.SZ) a purchase rating. The main reasons for the rating include: 1) the growth hormone sector is progressing steadily, and new businesses are growing
Tianfeng Securities released a research report on April 11 stating that it gave Changchun Hi-Tech (000661.SZ) a purchase rating. The main reasons for the rating include: 1) the growth hormone sector is progressing steadily, and new businesses are growing rapidly; 2) increasing investment in R&D and continuously improving the R&D network; 3) the research pipeline continues to advance, and the clinical progress of many new products is progressing smoothly. (Mainichi Keizai Shimbun)
Changchun Hi-Tech (000661): Growth hormone sector is steadily advancing research and development and continuous improvement
Incident: On March 20, the company released its 2023 annual report. In 2023, it achieved operating income of 14.566 billion yuan, an increase of 15.35% over the previous year; achieved net profit of 4.532 billion yuan, an increase of 9 percent over the previous year.
Changchun Hi-Tech (000661) 2023 Annual Report Review: The performance is in line with expectations and actively promotes the launch of new products
Incident: The company announced its 2023 annual report. In 2023, it achieved operating income of 14.566 billion yuan, an increase of 15.35% over the previous year; realized net profit of 4.532 billion yuan, an increase of 9.47% over the previous year. Single Q4 watch
Changchun Hi-Tech (000661.SZ): In the field of drug research and development, it has built various R&D innovation technology platforms, including long-term controlled release technology platforms for protein drugs, ADC drug technology platforms, special f
Gelonghui, March 28 | Changchun Hi-Tech (000661.SZ) said on the investor interactive platform that the company adheres to product development and introduction strategies with technological innovation as the lead, market demand as the guide, and clinical application value as the core, and continuously optimizes product iterations. In recent years, while ensuring stable performance, the company has rapidly raised the level of R&D investment, improved pipeline layout in multiple fields, actively expanded technical coverage, promoted global layout, promoted technological upgrading and process optimization of existing products, continuously enhanced multi-level R&D pipelines and rich project reserves, and strengthened the construction of innovative technology platforms. Built in the field of drug development
Changchun Hi-Tech (000661): Increased proportion of long-lasting water needles, steady progress in innovation and transformation
Incident: The company released its 2023 annual report, achieving operating income of 14.566 billion yuan, +15.35% year-on-year; net profit to mother of 4.532 billion yuan, +9.47% year-on-year; net profit excluding non-return to mother of 4.516 billion yuan
Communicating with investors but not being sincere enough? Changchun Hi-Tech's performance will attract “complaints” from shareholders | Direct hit on the performance conference
① At the results meeting held today, investors' questions about falling stock prices continued throughout; ② However, the responses provided by company executives were “undernourished”, which aroused more dissatisfaction among investors after the meeting; ③ The impact of the divorce incident of Jin Lei, the soul figure of Jinsai Biotech, on the company's stock price also drew a lot of questioning from investors.
Changchun Hi-Tech (000661.SZ): The share of the company's long-term water needles in growth hormone product revenue has increased to about 29% in 2023
Gelonghui March 25 丨 Changchun Hi-Tech (000661.SZ) held a performance briefing on March 25, 2024. Regarding “What is the current sales share of long-lasting growth hormone?” The company replied that in 2023, the company's share of growth hormone product revenue for long-acting water injections had increased to about 29%.
Changchun Hi-Tech (000661.SZ): Currently, the company's EG017 ointment is used for patients with dry eye and other indications in phase II clinical trials and continues to enroll
Gelonghui, March 25: An investor asked Changchun Hi-Tech (000661.SZ) on the investor interactive platform, “Can we talk about whether Gaoxin will enter the field of ophthalmology in the future?” The company replied that currently the company's EG017 ointment is used for patients with indications such as dry eye and phase II clinical trials.
Changchun High-Tech Industries (Group) Inc. Just Missed EPS By 6.6%: Here's What Analysts Think Will Happen Next
The annual results for Changchun High-Tech Industries (Group) Inc. (SZSE:000661) were released last week, making it a good time to revisit its performance. Revenues of CN¥15b were in line with f
No Data